Byrn, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
Bryn Inc. reports Q1 2026 results with significant management changes and a planned pivot to acquiring pharmaceutical distributors, aiming to leverage AI technology.
OTC.Pink
BYRN INC., a dormant shell company, reported continued operating losses in Q3 2025 and is actively seeking a reverse merger to acquire an operating business, facing significant financial and operational challenges.
OTC.Pink
BYRN INC. reported a net loss of $24,882 for the six months ended June 30, 2025, with no revenue and significant internal control weaknesses, as it continues to operate as a dormant shell company seeking a reverse merger.
OTC.Pink
Byrn Inc. reported no revenue and a net loss of $16,410 for the quarter ended March 31, 2025, as it continues to seek a business opportunity through a reverse merger.
OTC.Pink
Byrn Inc.'s latest quarterly report reveals ongoing operating losses and a continued search for potential business combinations to revitalize the company.
OTC.Pink
Born, Inc. reported continued financial losses and operational inactivity for the second quarter ended June 30, 2024, as it seeks a business combination to resume operations.
OTC.Pink
Born, Inc., a Nevada-based shell company, reported its unaudited financial results for the first quarter of 2024, showing no revenue and continued operating losses as it seeks a business combination.